CSPC Wins China Clinical Trial Nod for Next-Generation Obesity Drug SYH2069

CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.

CSPC Pharmaceutical Group has reported that its internally developed GLP-1/GIP receptor dual-biased agonist polypeptide injection, SYH2069, has received approval from China’s National Medical Products Administration to begin clinical trials, complementing an existing U.S. FDA clinical trial approval. Positioned as a potential first-in-class GLP-1/GIP dual-biased agonist in China, SYH2069 is designed to selectively activate the cAMP pathway while limiting receptor internalization and desensitization, aiming to enhance and prolong therapeutic effects; preclinical studies in obese animal models showed superior weight-loss and metabolic benefits versus marketed comparators, with a favorable tolerability profile. The initial clinical indication covers weight management in obese or overweight individuals with at least one weight-related comorbidity, and the drug also shows promise for improving glycemic control in adults with type 2 diabetes, underscoring CSPC’s ambition to strengthen its position in the fast-growing obesity and metabolic disease treatment market.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company engaged in the research, development and manufacturing of innovative drugs, with a focus on treatments for metabolic and other major diseases for the China and international markets.

YTD Price Performance: 88.72%

Average Trading Volume: 124,058,396

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$100.9B

See more insights into 1093 stock on TipRanks’ Stock Analysis page.